Vinpotropil
Vinpotropil: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Vinpotropile
ATX code: N06BX
Active ingredient: vinpocetine (vinpocetine) + piracetam (piracetam)
Producer: Deco company (Russia), Kanonpharma production CJSC (Russia)
Description and photo update: 2019-20-08
Prices in pharmacies: from 144 rubles.
Buy
Vinpotropil is a nootropic drug that improves cerebral circulation.
Release form and composition
Vinpotropil dosage forms:
- Film-coated tablets: oval, light brown with a grayish tinge, with a line, on a cross-section - almost white (10 pcs. In blisters, in a cardboard box 3 or 6 packs);
- Capsules: size No. 0, yellow with a red cap; contents - white powder, there may be individual lumps and crystals (10 pcs. in blister packs, in a cardboard bundle 2, 3, 5 or 10 packs; 15 pcs. in blister packs, in a carton pack 2, 4 or 6 packs; 15 or 50 pcs. In polyethylene bottles, in a cardboard box 1 bottle);
- Concentrate for preparation of solution for infusion: transparent, colorless or slightly colored (5 ml each in dark glass ampoules: 5 ampoules in a cardboard box; 5 ampoules in a blister strip, in a cardboard box 2 packs; 10 ampoules in a blister strip, in a cardboard box pack 1 or 2 packs).
Active ingredients in 1 tablet:
- Vinpocetine - 10 mg;
- Piracetam - 800 mg
Active ingredients in 1 capsule:
- Vinpocetine - 5 mg;
- Piracetam 400 mg
Active ingredients in 1 ml of concentrate:
- Vinpocetine - 1 mg;
- Piracetam - 80 mg
Excipients of tablets: croscarmellose sodium, calcium hydrogen phosphate dihydrate, povidone, magnesium stearate, microcrystalline cellulose, talc.
The composition of the tablet shell: brown opadry II (lactose monohydrate, macrogol, hypromellose, titanium dioxide, dyes of iron oxide red and iron oxide black).
Excipients of capsules: calcium stearate and lactose.
Concentrate excipients: sodium disulfite (sodium metabisulfite), succinic acid, ascorbic acid, water for injection.
Pharmacological properties
Pharmacodynamics
Vinpotropil is a combined agent, the action of which is determined by the properties of its active components: cerebrovasodilating (vinpocetine) and nootropic (piracetam).
Vinpocetine improves cerebral circulation, dilates the vessels of the brain, increases blood flow, improves the supply of glucose and oxygen to the brain. Facilitates the transport of oxygen and substrates of energy supply to tissues, thereby increasing the resistance of brain cells to hypoxia. Increases the content of catecholamines in brain tissues, and promotes the accumulation of cyclic adenosine monophosphate and adenosine triphosphate.
The vasodilating effect of vinpocetine is associated with its direct relaxing effect on the smooth muscles of blood vessels, especially the brain. Vinpotropil increases the blood supply to the ischemic region of the brain, while not causing the phenomenon of stealing and does not change the blood supply to intact brain areas. Increases the elasticity of erythrocytes, reduces platelet aggregation and reduces blood viscosity, thereby improving microcirculation in the brain.
Piracetam is a cyclic derivative of gamma-aminobutyric acid, has a nootopic effect. This substance has a direct effect on the brain, thereby improving performance and cognitive processes such as attention, memory and learning ability. It influences the central nervous system in various ways: it affects the rheological characteristics of blood, improves microcirculation, changes the rate of propagation of excitation in the brain, and improves metabolic processes in nerve cells. However, it does not have a vasodilating effect.
Vinpotropil improves cerebral blood flow, communication between the cerebral hemispheres and synaptic conduction in neocortical structures.
The drug inhibits platelet aggregation, restores the configuration properties of the outer membrane of rigid erythrocytes, normalizes the ability of rigid erythrocytes to pass through the vessels of the microvasculature.
At a dose of 9.6 g, Vinpotropil lengthens the bleeding time, reduces the concentration of fibrinogen and von Willebrand factor by 30-40%. It has a restorative and protective effect in case of dysfunction of the brain due to intoxication and hypoxia. Reduces the duration and severity of vestibular nystagmus.
Pharmacokinetics
Pharmacokinetic characteristics of the active components of Vinpotropil:
- vinpocetine: after taking the drug inside, it is rapidly absorbed in the gastrointestinal tract, mainly in its proximal parts. When passing through the intestinal wall, it is not metabolized. The maximum plasma concentration is reached within 1 hour. Therapeutic plasma concentrations of vinpocetine after oral and parenteral administration are 10–20 ng / ml. The bioavailability of the drug is 50–70%, the connection with proteins is 66%. The clearance is 66.7 l / h, this indicator exceeds the plasma volume of the liver (50 l / h), which indicates the extrahepatic metabolism of the drug. The main metabolite of vinpocetine is apovincaminic acid, which has little pharmacological activity. Other inactive metabolites are hydroxyapovincamine acid, hydroxyvinpocetin, and hydroxyvinpocetin glycinate. Pharmacokinetics with repeated use is linear. It is excreted by the kidneys and through the intestines in a ratio of 3: 2. It is excreted from the cerebrospinal fluid much more slowly than from other tissues. The half-life is an average of 4.8 hours (3.54-6.12). Easily penetrates the blood-brain barrier (including the blood-brain barrier), through the placental barrier and into breast milk;
- piracetam: penetrates well into various tissues and organs. In experiments on animals, it was found that the substance selectively accumulates in the tissues of the cerebral cortex, mainly in the occipital, parietal and frontal lobes, basal nuclei and cerebellum. It is characterized by a very high bioavailability - about 100%. After a single oral dose of 3.2 g, the maximum concentration is 84 μg / ml, after repeated use (3.2 g three times a day) - 115 μg / ml. The maximum concentration in plasma is reached within 1 hour, in the cerebrospinal fluid - within 5 hours. The volume of distribution is about 0.6 l / kg. The total clearance is 80–90 ml / min. Penetrates the blood-brain and placental barriers. Does not bind to plasma proteins. Practically not metabolized. It is excreted unchanged by the kidneys by glomerular filtration within 30 hours. The half-life from blood plasma is 4-5 hours, from the brain - 7.7 hours, from the cerebrospinal fluid - 8.5 hours. In chronic renal failure, the half-life is lengthened (up to 59 hours at the terminal stage). Piracetam is removed by hemodialysis.
Indications for use
For all dosage forms of Vinpotropil:
- Parkinsonism of vascular origin;
- Insufficiency of cerebral circulation (recovery period after hemorrhagic and ischemic stroke);
- Psychoorganic syndrome with a predominance of signs of adynamia and asthenia;
- Intoxication.
Additionally for tablets:
- Symptomatic treatment of vertigo;
- Chronic insufficiency of cerebral circulation of post-traumatic and hypertensive genesis;
- Prevention of kinetosis and migraine.
Additionally for capsules and concentrate for preparation of infusions:
- Labyrinthopathy;
- Asthenic syndrome;
- Brain trauma and other diseases of the central nervous system, accompanied by a decrease in intellectual and mnestic functions;
- Meniere's syndrome;
- Encephalopathy of various origins, including alcoholism.
In addition, Vinpotropil capsules are prescribed for the prevention of kinetosis and migraine.
Contraindications
Absolute:
- Acute stage of hemorrhagic stroke;
- Ischemic heart disease (severe course);
- Severe heart rhythm disturbances;
- Lactase deficiency, glucose-galactose malabsorption, lactose intolerance (for tablets);
- Renal / hepatic impairment;
- Age under 18;
- Pregnancy;
- Lactation;
- Hypersensitivity to Vinpotropil components.
Relative (due to the risk of complications, special care should be taken):
- Heavy bleeding;
- Violation of hemostasis;
- Viral hepatitis;
- Epilepsy;
- Alcoholic liver damage;
- Benign hyperbilirubinemia (including Gilbert's syndrome);
- Alcoholism;
- Elderly age;
- Deficiency of glucose-6-phosphate dehydrogenase (for tablets and capsules).
Instructions for the use of Vinpotropil: method and dosage
Film-coated tablets
In the form of tablets, Vinpotropil is taken orally with a sufficient amount of water, regardless of the meal, 1 pc. 2-3 times a day (the last dose should be about 4 hours before bedtime). Depending on the clinical picture, treatment can last from 2 weeks to 6 months, which is strictly determined by the doctor. It is recommended to gradually reduce the dose before discontinuing the drug.
Capsules
In the form of capsules, Vinpotropil is taken orally 1-2 pcs. 2-3 times a day (the last dose should be about 4 hours before bedtime). During maintenance therapy, the capsules are prescribed 1 pc. 3 times a day. Depending on the clinical picture, treatment can last from 2 weeks to 6 months. It is recommended to gradually reduce the dose before discontinuing the drug.
Concentrate for solution for infusion
Vinpotropil concentrate is injected intravenously at a rate of up to 80 drops per minute 1 time per day. A single dose is 2-3 ampoules, previously diluted with 500 ml of 0.9% sodium chloride solution or another solution containing dextrose. The duration of therapy is 10-14 days. If necessary, repeat the course after 6-8 weeks.
After improving the patient's condition, they are transferred to the oral form of Vinpotropil.
Side effects
- Cardiovascular system: changes in the electrocardiogram (lengthening of the QT interval, depression of the ST segment), lability of blood pressure, extrasystole, sensation of hot flashes, tachycardia, worsening of angina pectoris;
- Central nervous system: dizziness, irritability, headache, decreased ability to concentrate, sleep disturbances, imbalance, motor disinhibition, anxiety, ataxia, mental agitation, tremors, convulsions, extrapyramidal disorders (including hyperkinesis), depression;
- Digestive system: dry mouth, diarrhea, heartburn, nausea, gastralgia, vomiting;
- Skin: dermatitis, urticaria, redness, itching;
- Sense organs: vertigo;
- Others: weight gain, general weakness, asthenia, increased sweating, increased sexual activity, allergic reactions.
In addition, when using a concentrate to prepare a solution for Vinpotropil infusion, local reactions are possible: pain at the injection site and thrombophlebitis.
Overdose
In case of a significant excess of the dose of Vinpotropil, an increase in the severity of dose-dependent side effects, the occurrence of abdominal pain and diarrhea with an admixture of blood is possible. In the case of oral administration of the drug, gastric lavage and the intake of activated charcoal are recommended. Piracetam is excreted by 50-60% from the body using hemodialysis. There is no specific antidote. Further treatment is symptomatic.
special instructions
Patients who are diagnosed with a prolonged QT interval should periodically monitor the electrocardiogram during treatment.
Piracetam - one of the active ingredients of Vinpotropil - affects platelet aggregation, and therefore it is recommended to be careful when prescribing the drug to patients with hemostasis disorder, with symptoms of severe bleeding, as well as during major surgical operations.
Patients with lactose intolerance should take into account that 1 capsule contains about 225 mg of lactose.
Influence on the ability to drive vehicles and complex mechanisms
During treatment, care must be taken when driving and performing potentially hazardous activities.
Application during pregnancy and lactation
According to the instructions, Vinpotropil is contraindicated to take during pregnancy and lactation.
Pediatric use
In pediatric practice, the use of Vinpotropil is contraindicated.
With impaired renal function
Vinpotropil is prohibited in patients with severe chronic renal failure (creatinine clearance <20 ml / min).
For violations of liver function
Vinpotropil is prohibited in patients with hepatic impairment.
Use in the elderly
When prescribing the drug to elderly patients, caution is required.
Drug interactions
- Heparin: the risk of hemorrhagic complications increases;
- Psychostimulants, antipsychotics, thyroid hormones: their effects are enhanced;
- Indirect anticoagulants, including acenocoumarol: their effect is enhanced, there is a more pronounced decrease in platelet aggregation, the content of fibrinogen, von Willebrand factor, blood and plasma viscosity;
- Methyldopa: its hypotensive effect is enhanced (it is necessary to control blood pressure);
- Anticonvulsants: their effect is weakened, the seizure threshold decreases.
There are no data confirming the possibility of interaction of Vinpotropil with drugs of central and antiarrhythmic action, however, caution should be exercised when prescribing such a combination.
The concentrate for the preparation of solution for infusion is compatible with 5, 10 and 20% dextrose solutions, 5, 10 and 20% fructose solutions, Ringer's solution, 0.9% sodium chloride solution, 6 and 10% hydroxyethyl starch, 20% mannitol solution.
Analogs
Vinpotropil analogues are: Vinpocetine, Idebenone, Cavinton.
Terms and conditions of storage
Store at temperatures up to 25 ºС in a dry dark place out of reach of children.
Shelf life:
- Tablets, capsules - 2 years;
- Concentrate for solution preparation for infusion - 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Vinpotropil
Doctors speak positively about Vinpotropil. This drug is used in psychogeriatric practice (for the treatment of senile dementia), with cerebral circulatory failure, brain trauma, intoxication and other conditions accompanied by a decrease in intellectual and mental functions, as well as for the prevention of migraine and motion sickness.
Reviews of Vinpotropil from patients who took it are also predominantly positive. The drug significantly improves attention, memory and general well-being.
Vinpotropil price in pharmacies
The cost of capsules (5 mg + 400 mg) is approximately 157-190 rubles. per pack of 30 pcs. and 248-298 rubles. per pack of 60 pcs. A pack of 60 film-coated tablets (10 mg + 800 mg) can be purchased for 337–400 rubles. The price of Vinpotropil in the form of a concentrate for the preparation of an infusion solution is currently unknown.
Vinpotropil: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Vinpotropil 5 mg + 400 mg capsules 30 pcs. 144 RUB Buy |
|
Vinpotropil 10 mg + 800 mg film-coated tablets 30 pcs. RUB 150 Buy |
|
Vinpotropil 5 mg + 400 mg capsules 60 pcs. RUB 200 Buy |
|
Vinpotropil capsules 30 pcs. 206 RUB Buy |
|
Vinpotropil capsules 60 pcs. 248 r Buy |
|
Vinpotropil tablets p.p. 10mg + 800mg 30 pcs. 253 r Buy |
|
Vinpotropil 10 mg + 800 mg film-coated tablets 60 pcs. 280 RUB Buy |
|
Vinpotropil tablets p.p. 60 pcs. 486 r Buy |
| See all offers from pharmacies |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
